Tuesday, June 13, 2017 Enhanced Delivery of GDNF to Putamen in PD Shows No Clinical Benefit in Blind, page-2

The problem is OI that DBS will only help temporarily since it won't stop progression of the disease.

I suspect there is an opportunity for patients to have a one off treatment which will either halt the disease and in many patients reverse the symptoms and reduce the requirement for L-dopa. You seem to be convinced that patients in the initial trial cheated in the assessments. There really isn't any reason to believe that is true. Isn't it much more likely that patient #2 had an "off day" for one reason or another in the assessment at 105 weeks as I suggested?